Company intelligence / Profile preview
PharmatrophiX, Inc.
Menlo Park/San Francisco*, California, United Statespharmatrophix.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
PharmatrophiX has advanced its lead candidate LM11A‑31, a p75NTR ligand, into Phase 1 and subsequently Phase 2 trials for Alzheimer’s disease. The compound demonstrated safety in healthy volunteers and elderly subjects in Phase 1. Preclinical data show efficacy in animal models of Alzheimer’s disease by inhibiting tau phosphorylation and synaptic degeneration. Additional programs targeting TrkB/TrkC are at the preclinical stage.
- Therapeutic areas
- Neurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships publicly disclosed; prior funding from private investors and peer-reviewed grants including the Alzheimer’s Drug Discovery Foundation.
Beyond the preview
Go deeper on PharmatrophiX, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmatrophiX, Inc..